|
Volumn 305, Issue 19, 2011, Pages 2005-2006
|
From efficacy to effectiveness in the face of uncertainty: Indication creep and prevention creep
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ANTINEOPLASTIC AGENT;
HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;
CANCER STAGING;
CHRONIC LYMPHATIC LEUKEMIA;
CLINICAL EFFECTIVENESS;
COMORBIDITY;
COST EFFECTIVENESS ANALYSIS;
DRUG EFFICACY;
DRUG SAFETY;
FALSE NEGATIVE RESULT;
FALSE POSITIVE RESULT;
HEALTH CARE UTILIZATION;
HEART DISEASE;
HUMAN;
LYMPHOMA;
MINIMAL RESIDUAL DISEASE;
NOTE;
NUCLEAR MAGNETIC RESONANCE IMAGING;
OFF LABEL DRUG USE;
PATIENT CARE;
PHARMACEUTICAL CARE;
PRIMARY PREVENTION;
PRIORITY JOURNAL;
PROSTATE CANCER;
SECONDARY PREVENTION;
|
EID: 79956128884
PISSN: 00987484
EISSN: 15383598
Source Type: Journal
DOI: 10.1001/jama.2011.650 Document Type: Note |
Times cited : (92)
|
References (9)
|